title: Forensic dissection of a clinical trial: lessons learned in understanding and managing interstitial cystitis.
abstract: A pharmaceutical company-sponsored post-registration clinical trial designed to determine the most effective dose of pentosan polysulfate for the treatment of interstitial cystitis (IC) reported negative results. However, because of a priori trial design features, important posthoc analyses were able to answer many of the important clinical issues on the epidemiology, diagnosis, and treatment of IC that to date had remained unanswered. Seven published follow-up reports based on data and outcomes from the original study evaluated the clinical significance of a positive Potassium Sensitivity Test, confirmed the O'Leary-Sant Interstitial Cystitis Symptom Index as a valid and sensitive outcome measure, and determined that doses of pentosan polysulfate higher than the standard US Food and Drug Administration-approved dose of 300 mg/d did not increase efficacy although increased duration of therapy increases the chance of symptom amelioration. Further analyses determined that sexual dysfunction is an important parameter to assess in IC and that successful therapy can improve sexual functioning. Finally, the data showed that symptom severity, quality of life (QoL), and sleep function are interrelated. Consequently, symptom improvement with therapy correlates with improvement in both sleep function and QoL. This post hoc forensic dissection of a clinical trial initially undertaken for simple regulatory reasons has significantly improved our understanding and management of the enigmatic condition we call IC.
authors.affiliation: Department of Urology, Queen's University Kingston, Ontario, Canada.
authors.forename: J Curtis
authors.initials: JC
authors.lastname: Nickel
references.citation: Urology. 2002 Mar;59(3):329-33
references.pmid: 11880064
references.citation: J Urol. 1993 Sep;150(3):845-8
references.pmid: 7688432
references.citation: Urology. 1990 Jun;35(6):552-8
references.pmid: 1693797
references.citation: J Urol. 2009 Jun;181(6):2555-61
references.pmid: 19375108
references.citation: Urology. 2001 Jun;57(6 Suppl 1):62-6
references.pmid: 11378052
references.citation: Tech Urol. 1996 Fall;2(3):171-3
references.pmid: 9118427
references.citation: J Urol. 2003 Sep;170(3):810-5
references.pmid: 12913705
references.citation: J Sex Med. 2008 Feb;5(2):394-9
references.pmid: 18086174
references.citation: Urology. 2009 May;73(5):987-92
references.pmid: 19394494
references.citation: J Urol. 2007 May;177(5):1832-6
references.pmid: 17437831
references.citation: Urology. 2008 Jan;71(1):57-61
references.pmid: 18242365
references.citation: Med Clin North Am. 2004 Mar;88(2):467-81, xii
references.pmid: 15049588
references.citation: Urology. 2005 Apr;65(4):654-8
references.pmid: 15833501
references.citation: Urology. 1997 May;49(5A Suppl):58-63
references.pmid: 9146003
references.citation: J Urol. 1987 Sep;138(3):503-7
references.pmid: 2442415
references.citation: Curr Med Res Opin. 2008 Aug;24(8):2259-64
references.pmid: 18582395